Brady Family Wealth LLC Sells 2,687 Shares of Abbott Laboratories (NYSE:ABT)

Brady Family Wealth LLC lowered its position in Abbott Laboratories (NYSE:ABT - Free Report) by 4.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 59,445 shares of the healthcare product maker's stock after selling 2,687 shares during the quarter. Abbott Laboratories accounts for approximately 2.1% of Brady Family Wealth LLC's holdings, making the stock its 12th biggest holding. Brady Family Wealth LLC's holdings in Abbott Laboratories were worth $6,724,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in ABT. Insight Folios Inc grew its holdings in shares of Abbott Laboratories by 3.3% during the 3rd quarter. Insight Folios Inc now owns 2,691 shares of the healthcare product maker's stock worth $307,000 after purchasing an additional 87 shares in the last quarter. Sfmg LLC lifted its position in shares of Abbott Laboratories by 1.9% during the 3rd quarter. Sfmg LLC now owns 4,622 shares of the healthcare product maker's stock worth $527,000 after buying an additional 88 shares during the period. Boltwood Capital Management lifted its position in shares of Abbott Laboratories by 0.4% during the 3rd quarter. Boltwood Capital Management now owns 21,821 shares of the healthcare product maker's stock worth $2,488,000 after buying an additional 89 shares during the period. Wedge Capital Management L L P NC lifted its position in shares of Abbott Laboratories by 2.9% during the 3rd quarter. Wedge Capital Management L L P NC now owns 3,153 shares of the healthcare product maker's stock worth $359,000 after buying an additional 89 shares during the period. Finally, Silicon Valley Capital Partners lifted its position in shares of Abbott Laboratories by 8.7% during the 3rd quarter. Silicon Valley Capital Partners now owns 1,108 shares of the healthcare product maker's stock worth $126,000 after buying an additional 89 shares during the period. Hedge funds and other institutional investors own 75.18% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on ABT. Morgan Stanley raised their target price on Abbott Laboratories from $107.00 to $117.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 17th. Raymond James restated a "buy" rating and set a $129.00 target price (up previously from $122.00) on shares of Abbott Laboratories in a research report on Monday, October 14th. Barclays raised their target price on Abbott Laboratories from $143.00 to $149.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Jefferies Financial Group lifted their target price on Abbott Laboratories from $120.00 to $125.00 and gave the company a "hold" rating in a research note on Thursday, October 17th. Finally, Sanford C. Bernstein lifted their target price on Abbott Laboratories from $133.00 to $138.00 and gave the company an "outperform" rating in a research note on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $131.57.

Abbott Laboratories Trading Up 2.5 %

NYSE:ABT traded up $2.75 on Thursday, reaching $113.85. The company's stock had a trading volume of 5,595,969 shares, compared to its average volume of 4,940,966. Abbott Laboratories has a 1-year low of $99.71 and a 1-year high of $121.64. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The firm has a market cap of $197.47 billion, a PE ratio of 34.60, a PEG ratio of 2.40 and a beta of 0.73. The business's 50-day moving average price is $115.02 and its two-hundred day moving average price is $112.65.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.20 by $0.01. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. The firm had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $10.55 billion. During the same period in the previous year, the firm earned $1.14 earnings per share. The company's revenue was up 4.9% on a year-over-year basis. Equities research analysts anticipate that Abbott Laboratories will post 4.67 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be issued a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 2.07%. This is a positive change from Abbott Laboratories's previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Wednesday, January 15th. Abbott Laboratories's payout ratio is 66.87%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.